Muscular Dystrophy Association Celebrates 70 Years of Partnership with International Association of Fire Fighters
International Association of Fire Fighters & Affiliates Launch ‘Fill the Boot’ Fundraisers Nationwide for Muscular Dystrophy Association
10 avr. 2024 09h00 HE | Muscular Dystrophy Association
New York, April 10, 2024 (GLOBE NEWSWIRE) -- Muscular Dystrophy Association (MDA) celebrates 70 years of partnership with the International Association of Fire Fighters (IAFF) kicking off more...
AB Science annonce q
AB Science annonce que Santé Canada a jugé admissible la demande de réexamen du masitinib dans SLA
03 avr. 2024 12h09 HE | AB Science
COMMUNIQUE DE PRESSE AB SCIENCE ANNONCE QUE SANTÉ CANADA A JUGÉ ADMISSIBLE LA DEMANDE DE RÉEXAMEN DU MASITINIB DANS LA SCLÉROSE LATÉRALE AMYOTROPHIQUE Paris, 3 avril 2024, 18h AB Science SA...
AB Science announces
AB Science announces that Health Canada has granted eligibility for reconsideration request for masitinib in ALS
03 avr. 2024 12h09 HE | AB Science
PRESS RELEASE AB SCIENCE ANNOUNCES THAT HEALTH CANADA HAS GRANTED ELIGIBILITY FOR RECONSIDERATION REQUEST FOR MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS Paris, 3 April, 2024,...
Athira Pharma Logo RGB@1200px.jpg
Athira Pharma Announces Upcoming Poster Presentation at American Academy of Neurology (AAN) 2024 Annual Meeting
03 avr. 2024 07h00 HE | Athira Pharma, Inc.
BOTHELL, Wash., April 03, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing novel small molecules to restore neuronal...
Verge Logo.png
Verge Genomics and Ferrer Announce Agreement to Co-Develop Clinical-Stage ALS Therapy VRG50635
25 mars 2024 06h00 HE | Verge Genomics
SOUTH SAN FRANCISCO, Calif. and BARCELONA, Spain, March 25, 2024 (GLOBE NEWSWIRE) -- Verge Genomics, a leading clinical-stage biotechnology company, and Ferrer, an international B Corp...
AB Science : De nouv
AB Science : De nouvelles recherches montrent que le masitinib limite les dommages neuronaux dans un modèle de maladie neurodégénérative d’origine neuroimmune
13 mars 2024 07h59 HE | AB Science
COMMUNIQUÉ DE PRESSE DE NOUVELLES RECHERCHES MONTRENT QUE LE MASITINIB LIMITE LES DOMMAGES NEURONAUX DANS UN MODÈLE DE MALADIE NEURODÉGÉNÉRATIVE D'ORIGINE NEUROIMMUNE C'EST LA PREMIÈRE FOIS QUE LE...
AB Science: New rese
AB Science: New research shows that masitinib limits neuronal damage in a model of neuroimmune-driven neurodegenerative disease
13 mars 2024 07h59 HE | AB Science
PRESS RELEASE NEW RESEARCH SHOWS THAT MASITINIB LIMITS NEURONAL DAMAGE IN A MODEL OF NEUROIMMUNE-DRIVEN NEURODEGENERATIVE DISEASE THIS IS THE FIRST DEMONSTRATION THAT MASITINIB CAN LOWER SERUM...
How Do Companies Ave
How Do Companies Avert Further Frustration among Neurologists Due to Relyvrio’s (Amylyx) Phase 3 Failure and Donanemab’s (Lilly) FDA delay?
12 mars 2024 15h10 HE | Spherix Global Insights
EXTON, PA, March 12, 2024 (GLOBE NEWSWIRE) -- For neurologists tasked with delivering the distressing diagnosis of Amyotrophic Lateral Sclerosis (ALS) or Alzheimer’s Disease (AD), the upcoming...
Biosplice logo_final RGB 300 dpi_white background.png
Biosplice Therapeutics Announces Department of Defense (DoD) Award to Fund Collaboration with The Roskamp Institute to Advance its Neurology Program
08 mars 2024 13h36 HE | Biosplice Therapeutics, Inc.
Biosplice announced today that its collaboration with The Roskamp Institute has been awarded funding by the US Department of Defense.
July 30, 2021 - ROSEN LOGO.jpg
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AMLX
07 mars 2024 17h40 HE | The Rosen Law Firm PA
NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) between...